Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...

Zepbound is the preferred weight loss medicine vs. Wegovy and has consistently beaten the latter in U.S. weekly prescriptions ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.

Obesity drugmaker Novo Nordisk cut its sales forecasts on Wednesday for the first time since the launch of its Wegovy ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra. In this article, we will summarize the ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the ...

Novo Nordisk stock (NVO) jumped more than 5% in premarket trading Wednesday after beating Wall Street's profit estimates for ...

It became clear over the first quarter that the amount of business that had gone to the compounders was just significantly ...

Wegovy maker expects second-half rise in business that used to go to pharmacies’ custom-made ‘compounded’ versions ...